Acquisition Option Agreement of Scientific Nanomedicine, Inc., from Edward R. Flynn, Ph.D., by Manhattan Scientifics, Inc.
Exhibit 10.1
The confidential portions of this exhibit have been filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request in accordance with Rule 406 under the Securities Act of 1933, and Rule
24b-2, under the Securities Exchange Act of 1934, Redacted portions of this
exhibit are marked by an [***].
of
Scientific Nanomedicine, Inc., from Xxxxxx X. Xxxxx, Ph.D., by Manhattan
Scientifics, Inc.
This
Acquisition Option Agreement (“Agreement”) is made by and
among Senior Scientific LLC, a New Mexico limited liability company having a
place of business in Albuquerque, NM (“SS”), Xxxxxx X. Xxxxx, Ph.D.
("Xx. Xxxxx"), Scientific
Nanomedicine, Inc., a Delaware corporation ("SNMI") and Manhattan
Scientifics, Inc., a Delaware corporation having a place of business in New
York, New York (“MSI”),
and is effective as of ____________ (the “Effective Date”).
1.
|
Background.
|
1.1.
|
SNMI
is a corporation, wholly owned by Xx. Xxxxx, established for the
commercialization of technology owned by Xx. Xxxxx or SS, and generally
related to detection of biological materials, including detection and
treatment of cancer, with application to other areas of biology as
well.
|
1.2.
|
SS
and Xx. Xxxxx have previously assigned to SNMI all interest in technology
generally related to detection of biological materials, including
detection and treatment of cancer, with application to other areas of
biology as well, as set forth in the Technology Transfer Agreement between
Senior Scientific LLC and SNMI (the “Transfer Agreement”);
which Transfer Agreement has been provided to MSI and acknowledged by
MSI.
|
1.3.
|
MSI
advances technologies with potential world-changing impact to the
threshold of commercialization by following the principles of purpose,
dedication and cooperation.
|
1.4.
|
MSI
desires to obtain an option to acquire SNMI, including all IP assigned to
SNMI under the Transfer Agreement, for purposes of raising capital and
securing partnerships with industry leaders suitable for successful
commercialization of the technology, with the intent to exercise the
option and acquire SNMI if one or more large commercial partners can be
found to [***], and Xx. Xxxxx desires to grant the option
[***].
|
1.5.
|
[***].
|
2.
|
Definitions.
The following terms shall have the meanings set forth
below.
|
2.1.
|
Assigned IP. Assigned IP
as defined in the Transfer
Agreement.
|
2.2.
|
Affiliate. An “Affiliate” of a party is
any entity that, directly or indirectly, controls the party, is controlled
by the party, or is under common control with the
party.
|
3.
|
MSI Option to Acquire
SNMI.
|
3.1.
|
MSI
shall have the right to acquire 100% of the ownership of SNMI from Xx.
Xxxxx at any time during the Option Period (the “Option Period” is the
Initial Option Period and all applicable Extension
Periods).
|
3.2.
|
MSI
may exercise its option by giving Xx. Xxxxx written notice of exercise,
accompanied by payment of the Purchase
Price.
|
3.3.
|
The
Purchase Price shall be (a) US$[***], plus (b) [***] shares of the
restricted common stock of MSI, subject to applicable law and subject to
[***]. The Purchase Price shall be reduced by any payments and stock
issuances for extensions of the Option Period made by MSI prior to the
notice of exercise.
|
3.4.
|
Simultaneously
with receipt of the Purchase Price, Xx. Xxxxx shall transfer to MSI 100%
of the shares in SNMI.
|
4.
|
Option
Period.
|
4.1.
|
The
Option Period shall begin on the Effective Date and extend until the date
that is nine months after the Effective Date (the “Initial Option
Period”).
|
4.2.
|
If
MSI pays to Xx. Xxxxx US$[***] and [***] shares of the restricted common
stock of MSI, subject to applicable law and subject to [***] on or before
the end of the Initial Option Period (together the “First Payment”), then
the Option Period shall continue until the date that is [***] months after
the Effective Date (the “First Extension
Period”).
|
1
The confidential portions of this exhibit have been filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request in accordance with Rule 406 under the Securities Act of 1933, and Rule
24b-2, under the Securities Exchange Act of 1934, Redacted portions of this
exhibit are marked by an [***].
4.3.
|
If,
in addition to the First Payment, MSI issues to Xx. Xxxxx [***] shares of
the restricted common stock of MSI, subject to [***] (the “Second Payment”), on or
before the end of the First Extension Period, then the Option Period shall
continue under the date that is [***] months after the Effective Date (the
“Second Extension
Period”).
|
4.4.
|
If,
in addition to the First Payment and the Second Payment, MSI issues to Xx.
Xxxxx [***] shares of the restricted common stock of MSI, subject to [***]
(the “Third
Payment”), on or before the end of the Second Extension Period,
then the Option Period shall continue under the date that is [***] months
after the Effective Date (the “Third Extension
Period”).
|
4.5.
|
If
MSI does not exercise its option [***], then MSI shall have no rights to
acquire SNMI hereunder.
|
5.
|
Acquisition of
SNMI. Each Party consents to and approves of MSI’s acquisition of
SNMI, and acknowledges that the rights and obligations of SS, Xx. Xxxxx,
and SNMI under the Transfer Agreement will be unchanged by the change in
ownership of SNMI from Xx. Xxxxx to MSI. MSI acknowledges that it has
reviewed the Transfer Agreement and agrees that SNMI shall continue to
abide by its terms after any acquisition by MSI of the shares of SNMI
under this Agreement.
|
6.
|
IP Protection and
Filing During the Option
Period.
|
6.1.
|
MSI
will assist SNMI in developing an IP protection plan concerning the
Assigned IP.
|
6.2.
|
[***].
|
6.3.
|
SNMI,
Xx. Xxxxx, and SS acknowledge and agree that all patent applications filed
under this section are solely to protect MSI’s interest in the option to
acquire SNMI, and that neither MSI nor its counsel has any obligation to
SNMI, Xx. Xxxxx, or SS regarding such patent applications, including
without limitation the content, filing, and prosecution of such patent
applications. MSI, SNMI, SS, and Xx. Xxxxx all consent to the counsel of
MSI’s choosing to work on such patent applications, and acknowledge that
such counsel represents only MSI, and that SNMI, SS, and Xx. Xxxxx have
been advised to and have sought separate counsel regarding their interest
in this Agreement, including their interest, if any, in patent
applications under this section.
|
6.4.
|
During
the Option Period, MSI will act in a commercially reasonable manner to
protect the Assigned IP while MSI seeks to commercialize the Assigned
IP.
|
7.
|
Term and
Termination.
|
7.1.
|
This
Agreement shall be effective as of the Effective Date, and shall continue
until the end of the Option Period.
|
7.2.
|
Subject
to the Dispute Resolution provisions hereof, either party may assert
claims for damages or equitable relief due to the other party’s material
breach that remains uncured after a reasonable period in light of the
nature of the obligation, the nature of the breach, and any reasonable
opportunity to cure.
|
8.
|
Representations,
Warranties and Covenants.
|
8.1.
|
Each
of MSI, SNMI, and SS represents and warrants to the other that it is a
corporation (in the case of MSI and SNMI) or limited liability company (in
the case of SS) duly organized, validly existing, and in good standing
under the laws of its state of incorporation or organization, having a
place of business as set forth above, that it has the power and authority
to enter into this Agreement and that all corporate and other action
required to be taken on behalf of such party to authorize the execution
and delivery of this Agreement and to carry out the transactions
contemplated herein, has been duly and properly
taken.
|
8.2.
|
Each
of Xx. Xxxxx and SNMI represents and warrants that Xx. Xxxxx is the sole
owner of 100% of the shares of SNMI, and that no other party has any
rights to any shares or other ownership interest in SNMI, and that Xx.
Xxxxx has complete and sole authority to transfer the shares of SNMI, and
that such shares shall be fully paid and nonassessable. Each of Xx. Xxxxx
and SNMI represents, warrants, and covenants that no other party will be
granted any shares or other ownership interest or claim (including without
limitation any liens) to any shares or ownership interest in SNMI, and
that Xx. Xxxxx, at all times while this Agreement is in force, will have
complete and sole authority to transfer the shares, and that Xx. Xxxxx and
SNMI will execute all instruments necessary to accomplish such transfer as
set forth in this Agreement. SNMI and Xx. Xxxxx agree that all shares of
SNMI will have a legend placed thereon specifically referring to this
Agreement and MSI’s rights hereunder, and that, if any other party does
acquire any interest in the shares of SNMI, that such interest shall be
subject to MSI’s rights under this
Agreement.
|
2
The confidential portions of this exhibit have been filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request in accordance with Rule 406 under the Securities Act of 1933, and Rule
24b-2, under the Securities Exchange Act of 1934, Redacted portions of this
exhibit are marked by an [***].
8.3.
|
Each
of Xx. Xxxxx, SS, SNMI and MSI represents and warrants that it has
disclosed to the other Party any written or electronic mail communications
actually received by it which alleges it has violated or, by conducting
its obligations as currently proposed under this Agreement, would violate,
any of the Intellectual Property rights of any third
party.
|
8.4.
|
Each
of SS and Xx. Xxxxx represents that, to its actual knowledge, it owned and
had the right to assign the Assigned IP as set forth in the Transfer
Agreement; and that it obtained its rights fully in accordance with
applicable laws, rules and regulations; and that it has not granted any
licenses or other rights to any of the Assigned IP (except for reserved
rights to the US government in developments made under US government
grants); and covenants that it shall not grant any licenses or other
rights to any of the Assigned IP (except for reserved rights to the US
government in developments made under US government
grants). [***].
|
8.5.
|
Noncircumvent.
Each of Xx. Xxxxx and SS covenants that it will not solicit or engage in
business related to the Assigned IP or SNMI with any MSI-Referred Party
without MSI’s written consent. An “MSI-Referred Party” is
any party, and affiliates of any party, with whom MSI has done any of the
following: introduced the party to any of the Assigned IP, executed
written agreements relative to any of the Assigned IP, engaged in
negotiations relative to rights in any of the Assigned IP or
commercialization of any of the Assigned IP. If MSI has not exercised its
option at the expiration of the Option Period, then MSI will provide to
Xx. Xxxxx and SS a list of MSI-Referred Parties. This Noncircumvent
obligation shall extend for 5 (five) years after expiration of the Option
Period.
|
8.6.
|
Financing and
Cooperation. Xx. Xxxxx will cooperate with SNMI and MSI in the
commercialization of the Assigned IP, provided that MSI shall pay
[***].
|
8.7.
|
Right of First
Negotiation. If SS or Xx. Xxxxx proposes to sell or otherwise
dispose of any property that is specifically suited to any of the Assigned
IP (including, as examples, scientific instruments, research instruments,
and computer interfaces; but not including general office equipment or
supplies), then MSI shall be offered the first opportunity to purchase
such property upon mutually agreeable terms. MSI shall have 30 days from
the offer to negotiate the purchase, during which period MSI, SS, and Xx.
Xxxxx will negotiate in good faith the terms of the purchase, and then SS
and Xx. Xxxxx may consider other sales or
transfers.
|
9.
|
Miscellaneous.
|
9.1.
|
Further
Assurances. Each Party hereby agrees to execute and deliver any
further assignments and other documents as the other Party reasonably
believes to be necessary to effect the provisions of this Agreement, or
other enjoyment of the rights granted to such other Party
hereunder.
|
9.2.
|
Force Majeure.
The parties shall not be responsible for any failure to perform due to the
occurrence of any events beyond their reasonable control which render
their performance impossible or onerous. Xx. Xxxxx'x death or disability
shall not void the obligations of MSI under this
Agreement.
|
9.3.
|
Headings. The
headings of the articles, paragraphs, and clauses used in this Agreement
are included for convenience only and are not to be used in interpreting
or construing this Agreement.
|
9.4.
|
Governing Law.
This Agreement and all disputes concerning its execution, formation,
interpretation, performance, breach, termination, validity, or
enforceability shall be governed by and interpreted and enforced in
accordance with the laws of the United States of America and the State of
New Mexico, without regard to any principles of conflicts of law. In any
action brought arising out of this Agreement, including without limitation
any action to enforce the terms of this Agreement or to recover damages
from a breach of this Agreement, but not including actions against third
parties for infringement of IP rights, the parties agree to the exclusive
jurisdiction and venue of the state court of general jurisdiction and, if
appropriate, to a federal court sitting in the state of New Mexico, and
agree that neither party shall raise any objection to such personal
jurisdiction or venue.
|
3
The confidential portions of this exhibit have been filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request in accordance with Rule 406 under the Securities Act of 1933, and Rule
24b-2, under the Securities Exchange Act of 1934, Redacted portions of this
exhibit are marked by an [***].
9.5.
|
Trademarks and
Publicity. No party shall use any trademark of any other party
without first obtaining express written permission from the other. No
party shall make any public disclosure, including press releases,
disclosing the business relationship of any of the parties hereto or any
aspect thereof or identifying the other party, without the express written
permission of the party to be identified. MSI, SNMI, Xx. Xxxxx and SS will
cooperate in drafting a joint press release announcing the signing of this
Agreement, and on other joint press releases from time to time. Neither
party shall disclose specific terms of this Agreement, without the prior
consent of the other party or to the extent required by applicable law or
regulation, in which case the parties shall discuss the claimed lawful or
regulatory duty before making disclosure of all or any part of this
Agreement.
|
9.6.
|
Dispute
Resolution. Any disputes arising from or related to this Agreement
shall be addressed and resolved in three phases. First, an offended party
shall notify the other parties in writing of the events or occurrences
that give rise to a dispute. Within ten days of the actual receipt of the
notice, responsible representatives of the parties shall meet and, in good
faith, attempt to address and resolve the dispute through negotiation. If
the negotiations fail to resolve the dispute, the parties shall jointly
select a mediator and, within twenty days of the failed negotiations,
participate in mediation at a location within the State of New Mexico
selected by the mediator. Unless otherwise agreed by the parties, the
mediation shall conclude within forty-five days of the receipt of the
initial notice required under this paragraph. If the parties fail to
resolve fully their dispute through mediation, then any party may file a
lawsuit against another party.
|
9.7.
|
Attorney's
Fees. In the event legal proceedings arising out of or relating to
this Agreement are initiated by either party against the other, the
substantially prevailing party shall be entitled to recover its reasonable
expenses and costs, including attorneys’
fees.
|
9.8.
|
Waiver. No
claim or right arising out of a material breach of this Agreement can be
discharged in whole or in part by a waiver of the claim or rights unless
it is in writing and signed by the aggrieved
party.
|
9.9.
|
Notices. All
notices and other communications required herein shall be in writing and
shall be either delivered personally or be sent by certified mail, postage
prepaid, return receipt requested. Items delivered personally shall be
deemed delivered one day after dispatch; items sent by certified or
registered mail shall be deemed delivered three (3) days after mailing.
The addresses of the parties for purposes of this provision
are:
|
9.9.1.
|
MSI:
|
|
Chief
Executive Officer
|
|
Manhattan
Scientifics, Inc.
|
|
000
Xxxxxxx
|
|
Xxxxxxxx,
Xxxxxx X0X0X0 Xxxxxx
|
9.9.2.
|
SS
and Xx. Xxxxx:
|
|
Xxxxxx
Xxxxx, sole member of Senior Scientific
LLC
|
|
[***]
|
|
Xxxxxxxxxxx,
Xxx Xxxxxx 00000
|
9.9.3.
|
SNMI:
|
|
[***]
|
|
Xxxxxxxxxxx,
Xxx Xxxxxx 00000
|
9.10.
|
Entire
Agreement. This Agreement constitutes the entire agreement among
the parties hereto, and shall supersede the terms and conditions of any
and all prior agreements, understandings, promises, representations, and
writings made by either party to the other concerning the subject matter
and the terms and conditions hereof. No subsequent modification,
amendment, or extension of this Agreement or any of the terms and
conditions hereof shall be of any force or effect unless it is in writing
and signed by a duly authorized officer or representative of each of the
parties.
|
9.11.
|
Severability.
The unenforceability, invalidity, or illegality of any provisions of this
Agreement shall not render the other provisions unenforceable, invalid, or
illegal. Any unenforceable, invalid, or illegal provision shall be severed
from this Agreement only to the extent to make the resulting provision
enforceable, valid, and legal.
|
4
The confidential portions of this exhibit have been filed separately
with the Securities and Exchange Commission pursuant to a confidential treatment
request in accordance with Rule 406 under the Securities Act of 1933, and Rule
24b-2, under the Securities Exchange Act of 1934, Redacted portions of this
exhibit are marked by an [***].
9.12.
|
Counterparts.
This Agreement may be executed in counterparts with the same force and
effect as if all signatures appeared on the same
document.
|
9.13.
|
Good Faith. The
parties also promise at all times during the business relationship
established by this Agreement to execute and fulfill their contractual
obligations in good faith, and they, and each of them, expressly promise
at all times to treat each other fairly. All parties have had opportunity
to review this Agreement with counsel of their choice, and no provision
shall be construed for or against either party due to the identity of the
party drafting such provision.
|
9.14.
|
Bankruptcy. All
rights and licenses granted to each Party under or pursuant to this
Agreement are, and shall be deemed to be, for purposes of Section 365(n)
of the United States Bankruptcy Code, licenses to rights of “intellectual
property” as defined thereunder. Notwithstanding any provision contained
herein to the contrary, if either Party is under any proceeding under the
Bankruptcy Code and the trustee in bankruptcy of such Party, or such
Party, as a debtor in possession, rightfully elects to reject this
Agreement, the other Party may, pursuant to 11 U.S.C. Section 365(n) (1)
and (2) retain any and all of such other Party’s rights hereunder, to the
maximum extent permitted by law, subject to the payments specified
herein.
|
9.15.
|
Assignment. MSI
may assign, transfer, delegate or sublicense this Agreement or any of its
rights or obligations under this Agreement to an Affiliate of MSI. MSI may
not assign, transfer, delegate or sublicense any of its rights or
obligations under this Agreement to a party that is not an Affiliate of
MSI without the written consent of Xx. Xxxxx, which consent shall not be
unreasonably withheld or delayed. Neither Xx. Xxxxx nor SNMI may assign,
transfer, delegate, or sublicense this Agreement or any of its rights or
obligations under this Agreement without the written consent of MSI, which
consent shall not be unreasonably withheld or delayed.
[***].
|
INTENDING
TO BE LEGALLY BOUND, THE PARTIES, THROUGH THEIR AUTHORIZED AGENT(S), HAVE
EXECUTED THIS AGREEMENT AS OF THE DATE FIRST EXPRESSED ABOVE.
Senior
Scientific LLC
|
Scientific
Nanomedicine, Inc.,
|
|
Xxxxxx
X. Xxxxx, Ph.D., sole member
|
Xxxxxx
X. Xxxxx, Ph.D., president
|
|
Manhattan
Scientifics, Inc.
|
||
Xxxxxx
Xxxxx, Ph.D., an individual
|
Emmanuel
Tsoupanarias, CEO
|
5